ICGEB at the American Society of Gene & Cell Therapy ASGCT, 22nd Annual Meeting

New Preclinical Data with collaborators from ICGEB and the National Institutes of Health (NIH) reported by Selecta Biosciences in Washington D.C.

WATERTOWN, Mass., April 16, 2019 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR, today announced that five presentations of new preclinical data demonstrating the potential for the re-dosing of adeno-associated virus (AAV)-based gene therapy vectors when administered in combination with its ImmTOR (SVP-Rapamycin) platform will be presented by Selecta scientists and collaborators from the National Institutes of Health (NIH) and the International Centre for Genetic Engineering and Biotechnology (ICGEB) at the upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting from April 29 to May 2, 2019, in Washington, DC.

Read more about the work of the Mouse Molecular Genetics Group headed by Dr. Andres Muro.